Background for Promotions.png


Advanced Imaging Biomarkers in Alzheimer’s Disease

In this webinar, Drs. Lino Becerra and Phillip Kuo discuss the advances in imaging biomarkers in Alzheimer’s Disease (AD) with a focus on nuclear medicine and MRI. They take a deeper dive into:

Nuclear Medicine

  • A/T/N classification of AD biomarkers
  • Advances beyond binary amyloid PET interpretation
  • An update on Tau PET
  • Advances of Novel Imaging Biomarkers


  • Advances in MRI beyond volume quantification
  • Potential biomarkers for prediction and classification
  • Emerging machine learning approaches
Phillip Kuo, M.D., Ph.D. | Senior Medical Director, Invicro
Lino Becerra, Ph.D. | Vice President MRI, Invicro

Watch On Demand:

About The Speakers

Phillip Kuo, M.D., Ph.D.
Senior Medical Director, Invicro

Dr. Kuo is a tenured Professor in the Departments of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona. Beyond his academic work, Dr. Kuo has vast experience as a consultant, reader and speaker for CROs and pharmaceutical companies. Dr. Kuo has authored over 90 publications and has received numerous grants covering a diverse range of disciplines. Dr. Kuo received his A.B. from Harvard University, M.D. and Ph.D. from the University of Virginia, completed his Internal Medicine Residency at UCLA Medical Center, Diagnostic Radiology Residency at Yale New Haven Hospital, and Nuclear Medicine Fellowship at Yale New Haven Hospital. At Invicro, he supports the design, performance, and analysis of clinical trials and also supports regulatory approval and post-approval activities such as reader training.

Vice President MRI, Invicro

Lino Becerra, Ph.D. serves as Vice President of MRI to further consolidate and expand Invicro's capabilities to support studies utilizing MRI techniques from preclinical to clinical trials. Previously, Lino was the Co-Director for The Center for Pain and the Brain at Harvard Medical School as well as being a faculty member for over 20 years. He has worked extensively in neuroimaging applications in neurological conditions. He Co-Founded Descartes Therapeutics Inc., a biotech company that was dedicated to the development of drugs for chronic pain and was Co-Director of the Imaging Consortium for Drug Development, which was formed by Harvard, McLean Hospital, Massachusetts General Hospital, Merck, Eli Lilly and Sepracor Pharmaceuticals.